Modern methods for the development of new drugs that affect the hemostatic system
-
Published:2019-12-31
Issue:4
Volume:18
Page:136-152
-
ISSN:2414-9314
-
Container-title:Pediatric Hematology/Oncology and Immunopathology
-
language:
-
Short-container-title:Voprosy gematologii/onkologii i immunopatologii v pediatrii
Author:
Sulimov A. V.1ORCID, Kutov D. C.1, Tashchilova A. S.1ORCID, Ilin I. S.1ORCID, Podoplelova N. A.2ORCID, Panteleev M. A.3ORCID, Ledeneva I. V.4ORCID, Shikhaliev Kh. S.4ORCID, Sulimov V. B.2ORCID
Affiliation:
1. Research Computing Center, Lomonosov Moscow State University; Dimonta, Ltd 2. Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian Federation; Center for Theoretical Problems of Physicochemical Pharmakology 3. Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian Federation; Center for Theoretical Problems of Physicochemical Pharmakology; Lomonosov Moscow State University; Moscow Institute of Physics and Technology (State University 4. Voronezh State University
Abstract
The blood coagulation system plays an important role in health and disease. It is a complex network of proteolytic reactions that is activated during injuries and controls the formation of a fibrin clot. Although new components and reactions have not been discovered for thirty years, during this time there has been a revolution in understanding of how this system works and what enzymes are the optimal targets for the therapy. At the same time, new methods of drug development, first of all, computer docking, which are ideally suited for the discovery of inhibitors of blood clotting enzymes, have appeared. In this review, an attempt has been made to correlate the lines of development of new ideas about the mechanisms of coagulation, new methods of searching for drugs and their combination, thanks to which now there are more and more potentially interesting molecules that can change the face of the anticoagulant therapy in the near future. In the review, molecular modeling methods, primarily docking, which are increasingly used at the initial stage of developing new drugs, the role of docking at the initial stage of developing new inhibitors are briefly considered and the structure of the active centers of factors Xa and XIa, which determines their interaction with inhibitors, are discussed in detail.
Publisher
Fund Doctors, Innovations, Science for Children
Subject
Oncology,Hematology,Immunology,Immunology and Allergy,Pediatrics, Perinatology, and Child Health
Reference75 articles.
1. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., et al. The Protein Data Bank. Nucleic Acids Res 2000; 28: 235–42. 2. Sadovnichii V.A., Sulimov V.B. Superkomp'yuternye tekhnologii v meditsine. Superkomp'yuternye tekhnologii v nauke, obrazovanii i promyshlennosti. Moskva: Izdatel'stvo Moskovskogo universiteta, 2009; 1: 16–23. 3. Gupta M., Sharma R., Kumar A. Docking techniques in pharmacology: How much promising? Comput Biol Chem 2018; 76: 210–17. 4. Sulimov V.B., Sulimov A.V. Doking: molekulyarnoe modelirovanie dlya razrabotki lekarstv. – M.: OOO "Intell", 2017. 5. Sulimov A.V., Kutov D.K., Katkova E.V., Kondakova O.A., Sulimov V.B. Poisk podkhodov k uluchsheniyu tochnosti raschetov energii svyazyvaniya belok-ligand s pomoshch'yu dokinga. Izvestiya Akademii nauk. Seriya khimicheskaya. 2017: 1913–24.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|